A Phase 3, Open-label Study Evaluating the Long-Term Safety and Efficacy of VX-445 Combination Therapy in Subjects with Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a gating or Residual Function Mutation (F/G and F/RF Genotypes)

Grants and Contracts Details

StatusActive
Effective start/end date7/8/196/2/23

Funding

  • Vertex Pharmaceuticals Inc: $89,801.00